Drugs for Bladder Urothelial Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 120)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Bifidobacterium |
|
Phase 4 |
|
|
|
2 |
|
Acidophilus |
|
Phase 4 |
|
|
|
3 |
|
Aminolevulinic acid |
Approved |
Phase 3 |
|
106-60-5 |
137 |
Synonyms:
5 Aminolaevulinate
5 Aminolevulinate
5-ALA
5-Amino-4-oxopentanoate
5-Amino-4-oxo-pentanoate
5-Amino-4-oxopentanoic acid
5-Amino-4-oxo-pentanoic acid
5-Amino-4-oxovalerate
5-Amino-4-oxovaleric acid
5-Aminolaevulinate
5-Aminolaevulinic acid
5-Aminolevulinate
5-Amino-levulinate
5-Aminolevulinic acid
5-Amino-levulinic acid
Acid hydrochloride, aminolevulinic
Acid, aminolevulinic
Acid, Delta-aminolevulinic
|
ácido 5-aminolevulínico
Aladerm
Aminolevulinate
Aminolevulinic acid
Amino-levulinic acid
Aminolevulinic acid hydrochloride
Bertek brand OF aminolevulinic acid hydrochloride
dALA
Delta Aminolevulinic acid
delta-ALA
delta-Aminolevulinate
delta-Aminolevulinic acid
Hydrochloride, aminolevulinic acid
Kerastick
Levulan
δ-ALA
Δ-aminolevulinate
δ-aminolevulinic acid
|
|
4 |
|
Bevacizumab |
Approved, Investigational |
Phase 3 |
|
216974-75-3 |
135329020 |
Synonyms:
12-IGG1
ANTIVEGF
Anti-VEGF Humanized Monoclonal Antibody
Anti-VEGF monoclonal antibody
AVA-1
AVASTIN
Bevacizumab
BEVACIZUMAB BETA
bevacizumab-awwb
|
BI 695502
BS-503A
FKB-238
HLX04
HLX-04
R-435
RG-435
RHUMAB-
rhuMAb-VEGF
|
|
5 |
|
Carboplatin |
Approved |
Phase 3 |
|
41575-94-4 |
10339178 38904 |
Synonyms:
Blastocarb
Carboplat
CARBOPLATIN
Carboplatine
Carboplatino
Carbosin
Carbotec
Cbdca
CIS-(1,1-CYCLOBUTANEDICARBOXYLATO)DIAMMINEPLATINUM(II)
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM(II)
|
Ercar
JM 8
JM8
JM-8
Nealorin
Neocarbo
NSC-201345
NSC-241240
PARAPLATIN
Paraplatin-AQ
Ribocarbo
|
|
6 |
|
Docetaxel |
Approved, Investigational |
Phase 3 |
|
114977-28-5 |
148124 |
Synonyms:
CKD-810
Docecad®|docetaxel anhydrous|EmDOC|Taxotere®
DOCEFREZ
DOCETAXEL
Docetaxel anhydrous
Docetaxel hydrate
Docetaxel trihydrate
Docetaxel, trihydrate
Docetaxol
N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol
|
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol
NSC-628503
RP-56976
TAXCEUS
Taxoltere metro
Taxotere
TXL
XRP6976
|
|
7 |
|
Nivolumab |
Approved |
Phase 3 |
|
946414-94-4 |
|
Synonyms:
BMS-936558
BMS-936558|MDX-1106|ONO-4538|Opdivo®
MDX-1106
|
NIVOLUMAB
ONO-4538
OPDIVO
|
|
8 |
|
Atezolizumab |
Approved, Investigational |
Phase 3 |
|
1380723-44-3 |
|
Synonyms:
ANTI-PDL1
ANTI-PD-L1
ATEZOLIZUMAB
MPDL3280A
|
MPDL-3280A
RG-7446
TECENTRIQ
|
|
9 |
|
Fluorouracil |
Approved |
Phase 3 |
|
51-21-8 |
3385 |
Synonyms:
5 Fluorouracil
5 Fluorouracil biosyn
5 FU
5 FU lederle
5 FU medac
5 HU hexal
5.F.U.
5-Fluoracil
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluracil
5FU
5-FU
5-FU lederle
5-FU medac
5-HU hexal
ACCUSITE
ACTIKERALL
Adrucil
Allergan brand OF fluorouracil
Arumel
Biosyn brand OF fluorouracil
Carac
Carzonal
CSP Brand OF fluorouracil
Dakota brand OF fluorouracil
Dakota, fluorouracile
Dermatech brand OF fluorouracil
Dermik brand OF fluorouracil
Effluderm
Efudex
Efudix
Efurix
Ferrer brand OF fluorouracil
Fluoro Uracil
Fluoro uracile icn
Fluoroblastin
Fluoroplex
Fluorouracil
Fluorouracil gry
Fluorouracil mononitrate
Fluorouracil monopotassium salt
Fluorouracil monosodium salt
Fluorouracil potassium salt
FLUORO-URACIL ROCHE
Fluorouracil teva brand
|
Fluorouracile dakota
Fluoro-uracile icn
Fluorouracil-gry
Fluorouracilo
Fluorouracilo ferrer far
Fluorouracilum
Fluoruracil
Fluouracil
Fluracedyl
FLURACIL
Fluracilum
Fluri
Fluril
Fluro Uracil
Flurodex
Flurouracil
Ftoruracil
FU
Gry brand OF fluorouracil
Haemato brand OF fluorouracil
Haemato fu
Haemato-fu
Hexal brand OF fluorouracil
ICN brand OF fluorouracil
Kecimeton
Medac brand OF fluorouracil
Neocorp brand OF fluorouracil
Neofluor
NSC-19893
Onkofluor
Onkoworks brand OF fluorouracil
Pharmachemie brand OF fluorouracil monosodium salt
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Ribosepharm brand OF fluorouracil
Riemser brand OF fluorouracil
RO-29757
RO-2-9757
Roche brand OF fluorouracil
Teva brand OF fluorouracil
Timazin
TOLAK
Ulup
URF
|
|
10 |
|
BCG vaccine |
Approved, Investigational |
Phase 3 |
|
|
|
Synonyms:
BACILLUS CALMETTE GUERIN VACCINE
BACILLUS CALMETTE GUÉRIN VACCINE
Bacillus Calmette–Guérin (BCG) vaccine
|
Bacillus calmette-guerin live antigen, unspecified substrain
BCG
BCG vaccine
|
|
11 |
|
Mitomycin |
Approved |
Phase 3 |
|
50-07-7 |
5746 |
Synonyms:
7-Amino-9alpha-methoxymitosane
7-Amino-9a-methoxymitosane
7-Amino-9α-methoxymitosane
Ametycine
Mitamycin
Mitocin C
MitocinC
Mitocin-C
Mitomycin
|
Mitomycin C
Mitomycin-C
MITOSOL
MITOZYTREX
MMC
Muamycin
Mutamycin
MYTOZYTREX
NSC-26980
|
|
12 |
|
Gefitinib |
Approved, Investigational |
Phase 3 |
|
184475-35-2 |
123631 |
Synonyms:
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
GEFITINIB
Gefitinibum
Iressa
Iressa®|ZD 1839|ZD1839
Irressat
|
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
ZD 1839
ZD1839
ZD-1839
|
|
13 |
|
Ciprofloxacin |
Approved, Investigational |
Phase 3 |
|
85721-33-1, 93107-08-5 |
2764 |
Synonyms:
1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylate
1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid
1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate
1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylate
1-CYCLOPROPYL-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylate
1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid
1-CYCLOPROPYL-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylIC ACID
1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylate
1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylate
1-Cyclopropyl-6-fluoro-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylate
1-Cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Anhydrous, ciprofloxacin hydrochloride
Bacquinor
BAY O 9867 FREE BASE
Baycip
BAY-O-9867 FREE BASE
BAYQ3939
BAY-Q-3939
Bernoflox
CETRAXAL
Ciflox
Cifloxin
CILOXAN
Ciprinol
Cipro
Cipro I.V.
Cipro XL
Cipro XR
CIPROBAY
|
Ciprocinol
Ciprodar
Ciprofloxacin
Ciprofloxacin dihydrochloride
Ciprofloxacin HCl
Ciprofloxacin hydrochloride
Ciprofloxacin hydrochloride anhydrous
Ciprofloxacin monohydrochloride
Ciprofloxacin monohydrochloride monohydrate
Ciprofloxacina
Ciprofloxacine
Ciprofloxacino
Ciprofloxacinum
Cipromycin
Ciproquinol
Ciproxan
Ciproxin
CPFX
CPR867
Flociprin
Floxin
Hydrochloride anhydrous, ciprofloxacin
Hydrochloride, ciprofloxacin
Monohydrate, ciprofloxacin monohydrochloride
Monohydrochloride monohydrate, ciprofloxacin
Ocuflox
OTIPRIO
Proquin XR
Septicide
VELMONIT
Velomonit
|
|
14 |
|
Cephalexin |
Approved, Investigational, Vet_approved |
Phase 3 |
|
15686-71-2 |
27447 |
Synonyms:
(6R,7R)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
(6R,7R)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
66873
7-(D-a-Aminophenylacetamido)desacetoxycephalosporanate
7-(D-a-Aminophenylacetamido)desacetoxycephalosporanic acid
7-(D-alpha-Aminophenylacetamido)desacetoxycephalosporanate
7-(D-alpha-Aminophenylacetamido)desacetoxycephalosporanic acid
7-(D-Α-aminophenylacetamido)desacetoxycephalosporanate
7-(D-Α-aminophenylacetamido)desacetoxycephalosporanic acid
7-b-(D-a-Amino-a-phenylacetylamino)-3-methyl-3-cephem-4-carboxylate
7-b-(D-a-Amino-a-phenylacetylamino)-3-methyl-3-cephem-4-carboxylic acid
7-beta-(D-alpha-Amino-alpha-phenylacetylamino)-3-methyl-3-cephem-4-carboxylate
7-beta-(D-alpha-Amino-alpha-phenylacetylamino)-3-methyl-3-cephem-4-carboxylic acid
7-Β-(D-α-amino-α-phenylacetylamino)-3-methyl-3-cephem-4-carboxylate
7-Β-(D-α-amino-α-phenylacetylamino)-3-methyl-3-cephem-4-carboxylic acid
Anhydrous cefalexin
Anhydrous cephalexin
Cefalessina
Cefalexin
Cefalexin anhydrous
Cefalexina
Cefalexine
Céfalexine
Cefalexinum
Celexin
Cepastar
Cepexin
Cephacillin
CEPHALEXIN
Cephalexin 1-hydrate
Cephalexin anhydrous
|
Cephalexin dihydride
Cephalexin hemihydrate
Cephalexin hydrate
Cephalexin hydrochloride
Cephalexin monohydrate
Cephalexin monohydrochloride
Cephalexin monohydrochloride, monohydrate
Cephalexin, (6R-(6alpha,7alpha(r*)))-isomer
Cephalexin, (6R-(6alpha,7beta(s*)))-isomer
Cephalexin, (6R-(6alpha,7beta))-isomer
Cephalexin, monosodium salt
Cephalexin, monosodium salt, (6R-(6alpha,7beta))-isomer
Cephalexine
Cephalexinum
CEPOREX
Ceporexin
Ceporexine
CEX
Dihydride, cephalexin
Hemihydrate, cephalexin
Hydrochloride, cephalexin
KEFLET
Keflex
KEFTAB
Monohydrate cephalexin monohydrochloride
Monohydrate, cephalexin
Monohydrochloride, cephalexin
Monohydrochloride, monohydrate cephalexin
Monosodium salt cephalexin
Palitrex
|
|
15 |
|
Laevulinic Acid |
Experimental |
Phase 3 |
|
123-76-2 |
11579 |
Synonyms:
3-Acetylpropionate
3-Acetylpropionic acid
3-Ketobutane-1-carboxylate
3-Ketobutane-1-carboxylic acid
4-Ketovalerate
4-Ketovaleric acid
4-Oxopentanoate
4-Oxopentanoic acid
4-Oxovalerate
4-Oxovaleric acid
b-Acetylpropionate
b-Acetylpropionic acid
beta-Acetylpropionate
beta-Acetylpropionic acid
Calcium levulate
Calcium levulinate
Diasporal
FEMA NO. 2627
gamma-Ketovalerate
gamma-Ketovaleric acid
g-Ketovalerate
|
g-Ketovaleric acid
LAEVULINate
LAEVULINIC ACID
Laevulinsaeure
LEVA
Levulate
Levulic acid
Levulinate
Levulinic acid
Levulinic acid, ammonium salt
Levulinic acid, calcium salt
Levulinic acid, sodium salt
Levulinsaeure
Magnesium diasporal
Magnesium laevulinate
Magnesium levulinate
NSC-3716
Î’-acetylpropionate
Î’-acetylpropionic acid
Γ-ketovalerate
Γ-ketovaleric acid
|
|
16 |
|
Angiogenesis Inhibitors |
|
Phase 3 |
|
|
|
17 |
|
Photosensitizing Agents |
|
Phase 3 |
|
|
|
18 |
|
Vitamins |
|
Phase 3 |
|
|
|
19 |
|
Mitogens |
|
Phase 3 |
|
|
|
20 |
|
Endothelial Growth Factors |
|
Phase 3 |
|
|
|
21 |
|
Pharmaceutical Solutions |
|
Phase 3 |
|
|
|
22 |
|
Immunologic Factors |
|
Phase 3 |
|
|
|
23 |
|
Vaccines |
|
Phase 3 |
|
|
|
24 |
|
Protein Kinase Inhibitors |
|
Phase 3 |
|
|
|
25 |
|
Anti-Bacterial Agents |
|
Phase 3 |
|
|
|
26 |
|
Antibiotics, Antitubercular |
|
Phase 3 |
|
|
|
27 |
|
Adjuvants, Immunologic |
|
Phase 3 |
|
|
|
28 |
|
Fluoroquinolones |
|
Phase 3 |
|
|
|
29 |
|
Cytochrome P-450 Enzyme Inhibitors |
|
Phase 3 |
|
|
|
30 |
|
Aflibercept |
Approved |
Phase 2 |
|
862111-32-8 |
124490314 |
Synonyms:
AFLIBERCEPT
AFLIBERCEPT (GENETICAL RECOMBINATION)
AVE0005
AVE-0005
BAY86-5321
BAY-865321
|
BAY-86-5321
EYLEA
VEGF TRAP
VEGF TRAP-EYE
ZALTRAP
ZIV-AFLIBERCEPT
|
|
31 |
|
Bortezomib |
Approved, Investigational |
Phase 2 |
|
179324-69-7 |
387447 93860 |
Synonyms:
[(1R)-3-METHYL-1-({(2S)-3-PHENYL-2-[(PYRAZIN-2-YLCARBONYL)AMINO]PROPANOYL}AMINO)BUTYL]BORONIC ACID
341, PS
BORTEZOMIB
BORTEZOMIB HYDRATE
LDP 341
LDP-341
N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
|
NSC-681239
PEPTIDE BORONATE
peptide boronate|PS-341|Velcade®
PS 341
PS-341
Velcade
|
|
32 |
|
Arsenic trioxide |
Approved, Investigational |
Phase 2 |
|
1327-53-3 |
518740 |
Synonyms:
Acide Arsenieux
Acide Arsenieux [French]
Anhydride Arsenieux
Anhydride Arsenieux [French]
Arseni trioxydum
Arsenic Blanc
Arsenic Blanc [French]
Arsenic Oxide
Arsenic oxidearsenous trioxide
Arsenic Sesquioxide
ARSENIC TRIOXIDE
Arsenic Trioxide [UN1561] [Poison]
Arsenic(III) oxide
Arsenic, White
arsénico trióxido
Arsenicum Album
Arsenigen Saure
Arsenigen Saure [German]
Arsenious acid
Arsenious Acid Anhydride
Arsenious Oxide
Arsenious trioxide
Arsenite
|
Arsenolite
Arsenous Acid
Arsenous Acid Anhydride
Arsenous anhydride
Arsenous Oxide
Arsenous Oxide Anhydride
Arsentrioxide
Arsodent
Claudelite
Claudetite
Crude Arsenic
Diarsenic oxide
Diarsenic trioxide
Di-Arsenic Trioxide
Diarsonic Trioxide
HSDB 419
Naonobin
Oxyde Arsenieux [ISO-French]
Poison Flour
TRISENOX
Trixenox
White Arsenic
|
|
33 |
|
Ramucirumab |
Approved, Investigational |
Phase 2 |
|
947687-13-0 |
|
Synonyms:
1121B
CYRAMZA
Cyramza®|IMC-1121B
|
IMC-1121B
LY3009806
Ramucirumab
|
|
34 |
|
Epirubicin |
Approved |
Phase 2 |
|
56420-45-2 |
41867 |
Synonyms:
4' Epi adriamycin
4' Epi doxorubicin
4' Epi DXR
4' Epiadriamycin
4' Epidoxorubicin
4'-Epiadriamycin
4'-Epi-adriamycin
4'-Epidoxorubicin
4'-Epi-doxorubicin
4'-Epi-DXR
Cell pharm brand OF epirubicin
Ellence
EPI cell
Epiadriamycin
EPIcell
EPI-cell
Epidoxorubicin
Epi-Dx
Epilem
Epirubicin
Epirubicin hydrochloride
Epirubicina
Epirubicina [INN-Spanish]
Epirubicina [Spanish]
Epirubicine
|
Epirubicine [French]
Epirubicine [INN-French]
Epirubicinum
Epirubicinum [INN-Latin]
Epirubicinum [Latin]
Farmorubicin
Farmorubicina
Farmorubicine
Hydrochloride, epirubicin
IMI 28
IMI28
IMI-28
Kenfarma brand OF epirubicin hydrochloride
Lemery brand OF epirubicin hydrochloride
NSC-256942
Pfizer brand OF epirubicin hydrochloride
Pharmorubicin
Pharmorubicin Pfs
Pidorubicina
Pidorubicina [INN-Spanish]
Pidorubicine
Pidorubicine [INN-French]
Pidorubicinum
Pidorubicinum [INN-Latin]
Ridorubicin
|
|
35 |
|
Erlotinib |
Approved, Investigational |
Phase 2 |
|
183319-69-9, 183321-74-6 |
176870 |
Synonyms:
[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
[6,7-Bis(2-methoxy-ethoxy)quinazoline-4-yl]-(3-ethynylphenyl)amine
11C Erlotinib
11C-Erlotinib
CP-358
CP-358,774
CP-358774
CP-35877401
CP-358774-01
ERLOTINIB
Erlotinib HCL
Erlotinib hydrochloride
Erlotinibum
|
HCL, Erlotinib
Hydrochloride, erlotinib
N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
NSC 718781
NSC 718781|OSI 744|OSI-774|R 1415|Tarceva®
OSI 744
OSI 774
OSI-774
R 1415
R-1415
RG-1415
RO-508231
Tarceva
|
|
36 |
|
Altretamine |
Approved |
Phase 2 |
|
645-05-6 |
2123 |
Synonyms:
2,4,6-Tris(dimethylamino)-1,3,5-triazine
2,4,6-Tris(dimethylamino)-S-triazine
ALTRETAMIN
Altretamina
Altretamine
ALTRÉTAMINE
Altretamine bellon brand
Altretamine chiesi brand
Altretamine wassermann brand
Altretaminum
Bellon brand OF altretamine
Chiesi brand OF altretamine
Hemel
|
Hexalen
HEXAMETHYLMELAMINE
Hexastat
Hexinawas
HMM
HTM
HXM
MGI pharma brand OF altretamine
NSC-13875
Rhône poulenc rorer brand OF altretamine
Rhône-poulenc rorer brand OF altretamine
Wassermann brand OF altretamine
|
|
37 |
|
Propranolol |
Approved, Investigational |
Phase 2 |
|
318-98-9, 525-66-6 |
62882 4946 |
Synonyms:
(+-)-1-(ISOPROPYLAMINO)-3-(1-NAPHTHYLOXY)-2-PROPANOL HYDROCHLORIDE
1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol
1-(1-NAPHTHYLOXY)-2-HYDROXY-3-ISOPROPYLAMINOPROPANE HYDROCHLORIDE
1-(ISOPROPYLAMINO)-3-(1-NAPHTHOXY)-PROPAN-2-OL HYDROCHLORIDE
1-(ISOPROPYLAMINO)-3-(1-NAPHTHYLOXY)-2-PROPANOL HYDROCHLORIDE
1-(Isopropylamino)-3-(1-naphthyloxy)propan-2-ol
1-ISOPROPYLAMINO-3-(1-NAPHTHOXY)-PROPAN-2-OL-HYDROCHLORIDE
Anaprilin
Anapriline
ANGILOL
APSOLOL
Avlocardyl
AY-64043
AY-64043-
BEDRANOL
BEDRANOL S.R.
Bedranol®|Hemangiol®|Inderal®|propranolol hydrochloride
Beprane
BERKOLOL
Betachron
Betadren
BETADUR CR
Betalong
Beta-Neg
BETA-PROGRANE MR
beta-Propranolol
Beta-Tablinen
Beta-Timelets
b-Propranolol
CARDINOL
Caridolol
Corpendol
Deralin
Dexpropranolol
Dl-Propranolol Hydrochloride
Dociton
DUPROMEX
Duranol
Efektolol
Elbrol
Etalong
Euprovasin
Frekven
HALF BETA-PROGRANE MR
HALF PROPANIX LA
HALF PROPATARD LA
HALF-BEPRANE CR
HALF-BETADUR CR
HALF-INDERAL LA
HEMANGEOL
Hydrochloride, propranolol
ICI-45520
Inderal
INDERAL LA
|
Inderide
INDERIDE-40/25
INDERIDE-80/25
Indobloc
INNOPRAN
INNOPRAN XL
Intermigran
Kemi S
LEDERPRONOL
LOPRANOL LA
Migrastat
NSC-91523
Obsidan
Obzidan
Oposim
Prano-Puren
PROBETA LA
Propanalol
Propanix
PROPANIX LA
PROPANIX-10
PROPANIX-160
PROPANIX-160 SR
PROPANIX-40
PROPANIX-80
Propanolol
PROPATARD LA
Prophylux
Propranalol
PROPRANOLOL
PROPRANOLOL HCL
Propranolol Hcl Intensol
Propranolol hydrochloride
PROPRANOLOL HYDROCHLORIDE INTENSOL
Propranololo
Propranololum
Propranur
Proprasylyt
Pylapron
R,S-Propranolol Hydrochloride
RAPRANOL SR
Rapynogen
Reducor
Reducor Line
Rexigen
SAGITTOL
Servanolol
SLO-BLOK
SLO-PRO
SLOPROLOL
Sumial
SYPROL
TESNOL
Î’-propranolol
|
|
38 |
|
Tremelimumab |
Approved, Investigational |
Phase 2 |
|
745013-59-6 |
|
Synonyms:
CP-675,206
CP-675|CP-675,206|CP-675206|ticilimumab
CP-675206
|
TICILIMUMAB
TREMELIMUMAB
TREMELIMUMAB (GENETICAL RECOMBINATION)
|
|
39 |
|
Ipilimumab |
Approved |
Phase 2 |
|
477202-00-9 |
|
Synonyms:
BMS-734016
Ipilimumab
MDX-010
MDX-010|MDX-101|MDX-CTLA-4|Yervoy®
|
MDX-101
MDX-CTLA-4
MOAB-CTLA-4
YERVOY
|
|
40 |
|
Durvalumab |
Approved, Investigational |
Phase 2 |
|
1428935-60-7 |
|
Synonyms:
|
41 |
|
Daunorubicin |
Approved |
Phase 2 |
|
20830-81-3 |
30323 |
Synonyms:
(+)-Daunomycin
(8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
(8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
(8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
Acetyladriamycin
Anthracyline
Antibiotics From Streptomyces Coeruleorubidus
Cerubidin
Cerubidine
Daunamycin
Daunarubicinum
Dauno rubidomycine
Daunoblastin
Daunoblastine
Daunomycin
Daunomycin Hydrochloride
Daunomycin, Hydrochloride
Daunorrubicina
DAUNORUBICIN
Daunorubicin Hcl
Daunorubicin hydrochloride
Daunorubicin, Hydrochloride
DAUNORUBICINA
|
DAUNORUBICINE
Daunorubicinum
Daunorubicinum [INN-Latin]
Dauno-rubidomycine
DaunoXome
DM
DM1
FI 6339
FI-6339
Hydrochloride, daunorubicin
Leukaemomycin C
NDC-0082-4155
NSC-83142
Ondena
Rcra Waste No. U059
RP 13057
Rp 13057 Hydrochloride
RP-13057
Rubidomycin
Rubidomycin Hydrochloride
Rubomycin
Rubomycin C
VALRUBICIN IMPURITY, DAUNORUBICIN
|
|
42 |
|
Pemetrexed |
Approved, Investigational |
Phase 2 |
|
150399-23-8, 137281-23-3 |
60843 446556 135565230 |
Synonyms:
(2R)-2-{[4-(2-{4-hydroxy-2-imino-1H,2H,7H-pyrrolo[2,3-D]pyrimidin-5-yl}ethyl)phenyl]formamido}pentanedioate
ALIMTA
Alimta®|LY-231514
Disodium, pemetrexed
LY-2315
LY231514
|
LY-231514
MTA
N-(4-(2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-D)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid
NSC-698037
Pemetrexed
Pemetrexed disodium
|
|
43 |
|
Sirolimus |
Approved, Investigational |
Phase 2 |
|
53123-88-9 |
5284616 6436030 |
Synonyms:
(-)-Rapamycin
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-{(2S)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0(4,9)]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
Antibiotic ay 22989
AY-22989
AY-22989|Fyarro® (sirolimus albumin-bound particles)|Rapamune®|rapamycin|WY-090217
L04AA10
NSC-226080
Perceiva
RAPA
Rapammune
|
Rapamune
Rapamycin
Rapamysin
RPM
Sirolimus
Sirolimús
Sirolimusum
SM-88 COMPONENT SIROLIMUS
WY-090217
|
|
44 |
|
Dimethyl sulfoxide |
Approved, Vet_approved |
Phase 1, Phase 2 |
|
67-68-5 |
679 |
Synonyms:
(CH3)2SO
(Methylsulfinyl)methane
DIMETHYL SULFOXIDE
Dimethyl sulfoxixde
Dimethyl sulfur oxide
Dimethyl sulphoxide
Dimethyl sulphur oxide
Dimethyl sulpoxide
Dimethyli sulfoxidum
Dimethyli sulphoxidum
Dimethylsulfoxid
Dimethylsulfoxide
Dimethylsulfoxyde
Diméthylsulfoxyde
Dimethylsulphinyl
Dimethylsulphoxid
Dimethylsulphoxide
Dimethylsulphoxyde
Dimetil sulfoxido
Dimetil sulfóxido
Dimetil sulphoxido
Dimexide
DMSO
DOMOSO
|
INFILTRINA
Merckle brand OF dimethyl sulfoxide
Methylsulfinylmethane
Methylsulphinylmethane
NSC-763
Research ind. corp. brand 1 OF dimethyl sulfoxide
Research ind. corp. brand 2 OF dimethyl sulfoxide
Rheumabene
Rimso
rimso 100
Rimso 50
Rimso50
Rimso-50
S(O)Me2
Sclerosol
Shire brand OF dimethyl sulfoxide
SQ-9453
Sulfinylbis(methane)
Sulfoxide, dimethyl
Sulphinylbis(methane)
Sulphoxide, dimethyl
SYNTEXAN
Zymso
|
|
45 |
|
Lenograstim |
Approved, Investigational |
Phase 2 |
|
135968-09-1 |
|
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
GRANOCYTE-13
GRANOCYTE-34
Granulocyte colony stimulating factor 3 (CHO cell derived)
|
Granulocyte colony-stimulating factor lenograstim
Lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
RG-CSF
|
|
46 |
|
Gemcitabine |
Approved |
Phase 2 |
|
95058-81-4, 122111-03-9 |
60750 |
Synonyms:
2',2'-DFDC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-2',2'-difluorocytidine
2'-Deoxy-2',2''-difluorocytidine-5'-O-monophosphate
2'-Deoxy-2'-difluorocytidine
4-Amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
DDFC
DFDC
DFdCyd
Gemcin
GEMCITABIN
Gemcitabina
Gemcitabina [INN-Spanish]
GEMCITABINE
GEMCITABINE HCL
|
Gemcitabine hydrochloride
gemcitabine hydrochloride|Gemzar®
Gemcitabine, (alpha-D-threo-pentofuranosyl)-isomer
Gemcitabine, (beta-D-threo-pentafuranosyl)-isomer
Gemcitabine, (D-threo-pentafuranosyl)-isomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
GEO
INFUGEM
LY188011
LY-188011
LY188011 HYDROCHLORIDE
LY-188011 HYDROCHLORIDE
NSC-613327
|
|
47 |
|
Doxorubicin |
Approved, Investigational |
Phase 2 |
|
23214-92-8 |
31703 |
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
ADM
ADR
Adriablastin
Adriablastine
Adriamycin
Adriamycin PFS
Adriamycin RDF
Adriamycin Semiquinone
Adriamycin®|Caelyx® (liposomal doxorubicin)|Doxil®|doxorubicin hydrochloride
Adriblastin
Adriblastina
Adriblastine
Adrimedac
Baxter brand OF doxorubicin hydrochloride
Bedford brand OF doxorubicin hydrochloride
Bristol-myers squibb brand OF doxorubicin hydrochloride
Caelyx
Cell pharm brand OF doxorubicin hydrochloride
Columbia brand OF doxorubicin hydrochloride
DM2
DOXIL
Doxo
Doxo cell
Doxo-cell
Doxolem
DOXORUBICIN
Doxorubicin HCl
Doxorubicin hexal
Doxorubicin hydrochloride
|
Doxorubicin NC
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicina ferrer farm
Doxorubicina funk
Doxorubicina tedec
Doxorubicine
Doxorubicine [INN-French]
Doxorubicine baxter
Doxorubicinum
Doxorubicinum [INN-Latin]
Doxotec
Elan brand OF doxorubicin hydrochloride
Farmiblastina
Ferrer brand OF doxorubicin hydrochloride
Hexal brand OF doxorubicin hydrochloride
Hydrochloride, doxorubicin
HYDROXYDAUNORUBICIN
Kenfarma brand OF doxorubicin hydrochloride
Lemery brand OF doxorubicin hydrochloride
Medac brand OF doxorubicin hydrochloride
Myocet
Neocorp brand OF doxorubicin hydrochloride
NSC-123127
Onkodox
Onkoworks brand OF doxorubicin hydrochloride
Pfizer brand OF doxorubicin hydrochloride
Prasfarma brand OF doxorubicin hydrochloride
RDF Rubex
Resmycin
Ribodoxo
Ribosepharm brand OF doxorubicin hydrochloride
Rubex
Tedec meiji brand OF doxorubicin hydrochloride
Urokit doxo cell
Urokit doxo-cell
VALRUBICIN IMPURITY, DOXORUBICIN
|
|
48 |
|
Sunitinib |
Approved, Investigational |
Phase 2 |
|
557795-19-4 |
5329102 |
Synonyms:
5-(5-Fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
SU011248
SU-011248
SU11248
SU-11248
|
SU11248|Sutent®
SUNITINIB
Sunitinib malate
Sunitinibum
Sutent
|
|
49 |
|
Sorafenib |
Approved, Investigational |
Phase 2 |
|
284461-73-0 |
216239 |
Synonyms:
4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methyamide-4-methylbenzenesulfonate
4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
BAY 43-9006
BAY 43-9006|BAY-439006|Nexavar®
BAY-43-9006
N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
|
Nexavar
SORAFENIB
Sorafénib
Sorafenib N oxide
Sorafenib N-oxide
Sorafenib tosylate
Sorafenibum
|
|
50 |
|
Trastuzumab |
Approved, Investigational |
Phase 2 |
|
180288-69-1 |
|
Synonyms:
4D5V8
ABP 980
ABP-980
ANTI HER2
D5v8|Herceptin®|R-597
DMB-3111 (TRASTUZUMAB BIOSIMILAR)
EG12014
EG-12014
HERCEPTIN
IG GAMMA-1 CHAIN C REGION
KADCYLA
|
R-597
RHUMAB HER2
SYD977
SYD-977
TRASTUZUMAB
TRASTUZUMAB BETA
trastuzumab-anns
trastuzumab-dkst
trastuzumab-dttb
trastuzumab-pkrb
trastuzumab-qyyp
|
|
Interventional clinical trials:
(show top 50)
(show all 157)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
An Open Label, Randomized Control Study of Probiotics Administration in the Immunotherapy of Urothelial Bladder Carcinoma |
Recruiting |
NCT05220124 |
Phase 4 |
Live Combined (Bifidobacterium,Lactobacillus and Enterococcus Capsules) |
2 |
A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial Carcinoma |
Not yet recruiting |
NCT05488353 |
Phase 4 |
Disitamab Vedotin for Injection,Penpulimab Injection |
3 |
Adjuvant vs. Progression-Triggered Treatment With Gemcitabine After Radical Cystectomy for Locally Advanced Transitional Cell Carcinoma of the Bladder in Patients Not Suitable for Cisplatin-Based Chemotherapy - A Phase 3 Study |
Unknown status |
NCT00146276 |
Phase 3 |
gemcitabine |
4 |
A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine |
Completed |
NCT02101931 |
Phase 3 |
Amino levulinic Acid |
5 |
Randomized Phase III Trial Comparing Immediate Versus Deferred Chemotherapy After Radical Cystectomy in Patients With pT3-pT4, and/or N+M0 Transitional Cell Carcinoma (TCC) of the Bladder |
Completed |
NCT00028756 |
Phase 3 |
doxorubicin hydrochloride;gemcitabine hydrochloride;vinblastine sulfate;methotrexate;cisplatin |
6 |
Randomised Trial of Selective Bladder Preservation Against Radical Excision (Cystectomy) in Muscle Invasive T2/T3 Transitional Cell Carcinoma of the Bladder - Feasibility Study |
Completed |
NCT00867347 |
Phase 3 |
|
7 |
A Phase III Randomized Trial of Either M-VAC or Paclitaxel + Carboplatin as Postoperative Adjuvant Therapy in Patients With Muscle-Invasive Transitional Cell Carcinoma of the Bladder at High-Risk for Relapse |
Completed |
NCT00003701 |
Phase 3 |
carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine sulfate |
8 |
Phase III Study Comparing Sequential Chemotherapy (AG-ITP) To Cisplatin And Gemcitabine As Adjuvant Treatment After Cystectomy For Transitional Cell Carcinoma Of The Bladder |
Completed |
NCT00014534 |
Phase 3 |
cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride |
9 |
Megadose Vitamins as Chemoprevention of Transitional Cell Carcinoma of the Bladder |
Completed |
NCT00003623 |
Phase 3 |
|
10 |
A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma |
Completed |
NCT00942331 |
Phase 3 |
Cisplatin;Gemcitabine Hydrochloride |
11 |
A Phase III Randomized Trial of Eribulin (NSC #707389) With or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy |
Recruiting |
NCT04579224 |
Phase 3 |
Docetaxel;Eribulin Mesylate;Gemcitabine Hydrochloride;Paclitaxel |
12 |
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial (IMAGINE) |
Recruiting |
NCT04637594 |
Phase 3 |
Pembrolizumab;Nivolumab;Atezolizumab;Durvalumab;Avelumab |
13 |
MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients With Metastatic Urothelial Cancer |
Recruiting |
NCT05092958 |
Phase 3 |
Avelumab;Cabozantinib S-malate |
14 |
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer |
Recruiting |
NCT03775265 |
Phase 3 |
Atezolizumab;Cisplatin;Fluorouracil;Gemcitabine;Mitomycin |
15 |
Neoadjuvant Chemotherapy in Upper Tract Urothelial Cancer: A Multicentre, Feasibility Pilot Trial |
Recruiting |
NCT04574960 |
Phase 3 |
Gemcitabine;Cisplatin;Carboplatin |
16 |
S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer |
Active, not recruiting |
NCT03091660 |
Phase 3 |
|
17 |
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation |
Active, not recruiting |
NCT03244384 |
Phase 3 |
|
18 |
A Multicenter, Randomized, Double-blind, Controlled Phase III Non-inferiority Study Assessing Efficacy and Safety of VERITY-BCG in Management of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC) in BCG-naïve Patients. |
Not yet recruiting |
NCT05037279 |
Phase 3 |
Bacillus Calmette-Guerin: Strain Russian BCG-I;Bacillus Calmette-Guerin: Strain TICE |
19 |
A Randomized Controlled Study Comparing Adjuvant Hyperthermia Treatment in Conjunction With Mitomycin C Versus BCG Immunotherapy (BCG) Adjuvant Treatment in Patients With Superficial Transitional Cell Carcinoma of the Bladder (STCCB) |
Terminated |
NCT00384891 |
Phase 3 |
Bacillus Calmette-Guérin |
20 |
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Multicenter Study of Immediate Postoperative Instillation of Gemcitabine in Patients With Superficial Transitional Cell Carcinoma of the Bladder |
Terminated |
NCT00191477 |
Phase 3 |
Gemcitabine;Placebo |
21 |
A Phase III Study of IRESSA in Combination With Intravesical BCG Versus Intravesical BCG Alone in High Risk Superficial Transitional Cell Carcinoma of the Bladder |
Terminated |
NCT00352079 |
Phase 3 |
gefitinib |
22 |
The Effect of Fluoroquinolones on the Disease-Free Interval in Patients With Stage Ta Transitional Cell Carcinoma of the Bladder |
Terminated |
NCT00003824 |
Phase 3 |
cephalexin;Ciprofloxacin |
23 |
A Phase II Study Investigating Preoperative MPDL3280A in Operable Transitional Cell Carcinoma of the Bladder (ABACUS) |
Unknown status |
NCT02662309 |
Phase 2 |
MPDL3280A |
24 |
A Phase II Study of Neoadjuvant Cisplatin and Gemcitabine Plus Sorafenib for Patients With Transitional-Cell Carcinoma of the Bladder |
Unknown status |
NCT01222676 |
Phase 2 |
cisplatin;gemcitabine hydrochloride;sorafenib tosylate |
25 |
A Phase Ib/II Trial of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer |
Unknown status |
NCT01326871 |
Phase 1, Phase 2 |
Cisplatin;Gemcitabine |
26 |
A Phase II, Open, Multi-center and Single Arm Study Investigating Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Injection in Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma |
Unknown status |
NCT03113266 |
Phase 2 |
|
27 |
A Phase II Safety and Efficacy Study With the VEGF Receptor Tyrosine Kinase Inhibitor GW786034 in Patients With Metastatic Urothelial Cancer |
Completed |
NCT00471536 |
Phase 2 |
pazopanib hydrochloride |
28 |
A Phase II Study of Gemcitabine, Paclitaxel, and Doxorubicin, With Pegfilgrastim for the Treatment of Patients With Metastatic Transitional Cell Carcinoma and Renal Insufficiency |
Completed |
NCT00478361 |
Phase 2 |
Gemcitabine hydrochloride;Paclitaxel;Doxorubicin hydrochloride;Pegfilgrastim |
29 |
A Phase 1/2a Pilot Study of Intravesical TSD-001 for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer |
Completed |
NCT03081858 |
Phase 1, Phase 2 |
TSD-001 |
30 |
A Phase II Study of VEGF Trap (NSC 724770) in Patients With Recurrent or Metastatic Transitional Carcinoma of the Urothelium |
Completed |
NCT00407485 |
Phase 2 |
|
31 |
Phase II Trial of PS-341 (Bortezomib) in Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma |
Completed |
NCT00072150 |
Phase 2 |
bortezomib |
32 |
Phase II Evaluation of Trastuzumab (Herceptin), Paclitaxel, Carboplatin, and Gemcitabine in the Treatment of Advanced Urothelial Cancer |
Completed |
NCT00005831 |
Phase 2 |
paclitaxel;carboplatin;gemcitabine hydrochloride |
33 |
A Phase II Study of BAY 43-9006 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter and Renal Pelvis) |
Completed |
NCT00112671 |
Phase 2 |
sorafenib tosylate |
34 |
A Phase II Study Of Epothilone B Analogue BMS-247550 (NSC #710428) q21 Days In Advanced Carcinoma Of The Urothelium |
Completed |
NCT00021099 |
Phase 2 |
ixabepilone |
35 |
A PHASE II STUDY OF ARSENIC TRIOXIDE (NSC #706363, IND #57974) IN UROTHELIAL CANCER |
Completed |
NCT00009867 |
Phase 2 |
arsenic trioxide |
36 |
Prospective Phase II Randomized Trial of Prostate Capsule Sparing Cystectomy and Nerve-sparing Radical Cystoprostatectomy in Men With Bladder Cancer |
Completed |
NCT01824329 |
Phase 2 |
|
37 |
Multicenter Randomized Phase 2 Trial of Gemcitabine - Platinum With or Without Trastuzumab in Advanced or Metastatic Urothelial Carcinoma With HER2 Overexpression |
Completed |
NCT01828736 |
Phase 2 |
Gemcitabine;Carboplatin;Cisplatin |
38 |
A Phase 2 Study of the Aurora Kinase A Inhibitor Alisertib (MLN8237) in Patients With Relapsed or Refractory Transitional-cell Carcinoma of the Bladder and Urothelial Tract |
Completed |
NCT02109328 |
Phase 2 |
Alisertib;Paclitaxel;Placebo |
39 |
Phase II Single Arm, Open Label, Single Institution Study of Neoadjuvant Sunitinib (SUTENT) in Patients With Muscle-Invasive Locally Advanced Transitional Cell Carcinoma of the Bladder |
Completed |
NCT00526656 |
Phase 2 |
sunitinib malate |
40 |
Phase II Trial of Paclitaxel, Carboplatin and Gemcitabine in Patients With Locally Advanced Transitional Cell Carcinoma of the Bladder |
Completed |
NCT00136175 |
Phase 2 |
Paclitaxel;Carboplatin;Gemcitabine |
41 |
Phase II Evaluation of Robotic-assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Transitional Cell Carcinoma of the Bladder |
Completed |
NCT00963859 |
Phase 2 |
|
42 |
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy |
Completed |
NCT01282463 |
Phase 2 |
Docetaxel |
43 |
Phase II Study of the Fully Human Monoclonal Antibody Against Transforming Growth Factor-beta (TGFβ) Receptor ALK1 (PF-03446962) in Relapsed or Refractory Urothelial Cancer (UC) Failing First-line Treatment. |
Completed |
NCT01620970 |
Phase 2 |
PF03446962 |
44 |
Clinical Study of Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder After Surgical Management |
Completed |
NCT00343356 |
Phase 2 |
Trement |
45 |
A Phase II Study of R115777 (Zarnestra) in Superficial Transitional Cell Carcinoma of Bladder |
Completed |
NCT00047216 |
Phase 2 |
tipifarnib |
46 |
Randomized Phase II Study Assessing the Combination of Vinflunine With Gemcitabine and Vinflunine With Carboplatin in Patients Ineligible to Cisplatin With Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium |
Completed |
NCT01599013 |
Phase 2 |
Vinflunine, Gemcitabine;Vinflunine, Carboplatin |
47 |
Acupuncture vs. Standard of Care for Induction Intravesical BCG-Related Adverse Events in High-Risk Non-Muscle Invasive Bladder Cancer |
Completed |
NCT04496219 |
Phase 2 |
|
48 |
Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder |
Completed |
NCT02178241 |
Phase 2 |
Eribulin Mesylate;Gemcitabine Hydrochloride |
49 |
A Phase II Exploratory Study of Pre-Operative Treatment With Erlotinib (Tarceva) in Muscle Invasive or Recurrent Transitional Cell Carcinoma Requiring Cystectomy |
Completed |
NCT00749892 |
Phase 2 |
Erlotinib Hydrochloride |
50 |
A Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates With Muscle-Invasive Bladder Cancer |
Completed |
NCT00238420 |
Phase 1, Phase 2 |
Paclitaxel |
|